Tracers / [177Lu]Lu-DOTA-POL3026
[177Lu]Lu-DOTA-POL3026
Also written as [Lu-177]Lu-DOTA-POL3026
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated CXCR4-targeting peptide
- Target / mechanism
- CXCR4 (C-X-C chemokine receptor 4) PMID 39008219
- Clinical application
- Preclinical targeted radionuclide therapy (TRT) for glioblastoma PMID 39008219
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >95% | >95% | DOTA-POL3026 CSBio, California, US | 39008219 2024 EJNMMI Radiopharm Chem [177Lu]LuCl3 was added to the DOTA-conjugated peptides in 0.15 M NaOAc buffer, pH 4.7, with a total reaction volume of 0.25–0.35 mL, and reacted at 95 °C for 30 min with gentle shaking — All three DOTA-conjugated peptides could be radiolabelled with 177Lu with > 95% radiochemical yield. |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-POL3026, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39008219. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39008219: 'DOTA-CTCE9908, DOTA-DV1-K-DV3, and DOTA-POL3026 were obtained from the custom peptide synthesis service of CSBio (California, US)'.